COYA vs. RNAC, IMUX, ABEO, CLRB, VTGN, OPTN, RZLT, KPTI, RLMD, and PMVP
Should you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include Cartesian Therapeutics (RNAC), Immunic (IMUX), Abeona Therapeutics (ABEO), Cellectar Biosciences (CLRB), Vistagen Therapeutics (VTGN), OptiNose (OPTN), Rezolute (RZLT), Karyopharm Therapeutics (KPTI), Relmada Therapeutics (RLMD), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical preparations" industry.
Coya Therapeutics (NASDAQ:COYA) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership.
Coya Therapeutics and Cartesian Therapeutics both received 8 outperform votes by MarketBeat users. However, 100.00% of users gave Cartesian Therapeutics an outperform vote while only 88.89% of users gave Coya Therapeutics an outperform vote.
Coya Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -983.93%. Coya Therapeutics' return on equity of -45.11% beat Cartesian Therapeutics' return on equity.
39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 9.8% of Coya Therapeutics shares are owned by company insiders. Comparatively, 31.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Cartesian Therapeutics had 10 more articles in the media than Coya Therapeutics. MarketBeat recorded 18 mentions for Cartesian Therapeutics and 8 mentions for Coya Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.74 beat Coya Therapeutics' score of 0.25 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.
Coya Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
Coya Therapeutics has higher earnings, but lower revenue than Cartesian Therapeutics.
Coya Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 64.71%. Cartesian Therapeutics has a consensus target price of $45.00, suggesting a potential upside of 70.84%. Given Cartesian Therapeutics' higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Coya Therapeutics.
Summary
Cartesian Therapeutics beats Coya Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Coya Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coya Therapeutics Competitors List
Related Companies and Tools
